The Vascular Endothelial Growth Factor Receptor 3 pipeline drugs market research report outlays comprehensive information on the Vascular Endothelial Growth Factor Receptor 3 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Vascular Endothelial Growth Factor Receptor 3 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Oncology, Ophthalmology, Genetic Disorders, and Respiratory which include the indications Solid Tumor, Hepatocellular Carcinoma, Wet (Neovascular / Exudative) Macular Degeneration, Diabetic Macular Edema, Polycystic Kidney Disease, Familial Adenomatous Polyposis, Idiopathic Pulmonary Fibrosis, and Interstitial Lung Fibrosis. It also reviews key players involved in Vascular Endothelial Growth Factor Receptor 3 targeted therapeutics development with respective active and dormant or discontinued products.
The Vascular Endothelial Growth Factor Receptor 3 pipeline targets constitutes close to 44 molecules. Out of which, approximately 43 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Filing rejected/ Withdrawn, Phase III, Phase II, Phase I, and Preclinical stages are 3, 2, 13, 10, 7, and 8 respectively. Similarly, the universities portfolio in Discovery comprises 1 molecule.
Vascular Endothelial Growth Factor Receptor 3 overview
Vascular endothelial growth factor receptor 3 (VEGFR-3), also known as FLK4, is a transmembrane tyrosine kinase receptor that plays a crucial role in lymphangiogenesis, the process of lymphatic vessel formation. It is primarily expressed on lymphatic endothelial cells (LECs) but can also be found in some tumor cells and blood endothelial cells. VEGFR-3 binds to its ligands, VEGF-C and VEGF-D, to activate a signaling cascade that promotes LEC proliferation, migration, and survival, leading to the growth and expansion of the lymphatic network.
For a complete picture of Vascular Endothelial Growth Factor Receptor 3’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
